← Leaderboards
Robert B Ettenger
University Of California Los Angeles
$858,654
Attributed
$858,654
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $13.1K · FY2007–09$20K$15K$10K$5K$0
'07
'08
'09
Funding mix
By agency
NIH$858,654 · 5
By mechanism
M01$858,654 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Mary J Rotheram-Borus$67,342,409
- Dinesh Khanna$4,798,098
- Betty P. Tsao$10,303,823
- Donald P Tashkin$15,930,292
- Dallas Travis Swendeman$6,765,170
Others in their field
Top investigators on “Kidney Transplantation”
- Peter Scott Heeger · Case Western Reserve University$86,758,000
- Joren C Madsen · Massachusetts General Hospital$51,129,981
- Dorry Segev · Johns Hopkins University$40,143,271
- Peter G Stock · University Of California San Francisco$37,405,503
- Robert M Merion · University Of Michigan At Ann Arbor$29,566,275
- John C Magee · University Of Michigan At Ann Arbor$28,786,531
Research focus
Kidney TransplantationClinical ResearchHuman SubjectTransplant RejectionDrug Screening /EvaluationHomologous TransplantationChronic Disease /DisorderChronic Renal FailureClinical Trial Phase IComparative TrialComputer Retrieval Of Information On Scientific Projects DatabaseDaclizumabDialysis TherapyEnrollmentFundingGrantHuman Therapy EvaluationImmunosuppressiveInstitutionMycophenolate MofetilNatural ImmunosuppressionPediatric PharmacologyPharmacokineticsPostoperative State
Grant awards (9)
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND$5,603
M01 · FY2009 · RR · contact PI
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND$7,130
M01 · FY2008 · RR · contact PI
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND$13,051
M01 · FY2007 · RR · contact PI
RECOMBINANT HUMAN GROWTH HORMONE (NUTROPIN) IN POST RENAL TRANSPLANTED CHILDREN$207,266
M01 · FY2001 · RR
PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX$207,266
M01 · FY2001 · RR
RECOMBINANT HUMAN GROWTH HORMONE (NUTROPIN) IN POST RENAL TRANSPLANTED CHILDREN$207,266
M01 · FY2000 · RR
PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX$207,266
M01 · FY2000 · RR
PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX$1,903
M01 · FY2000 · RR
RECOMBINANT HUMAN GROWTH HORMONE (NUTROPIN) IN POST RENAL TRANSPLANTED CHILDREN$1,903
M01 · FY2000 · RR